{
 "cells": [
  {
   "cell_type": "code",
   "id": "initial_id",
   "metadata": {
    "collapsed": true,
    "ExecuteTime": {
     "end_time": "2025-05-07T16:17:19.672266Z",
     "start_time": "2025-05-07T16:16:40.967979Z"
    }
   },
   "source": [
    "import requests\n",
    "import json\n",
    "import numpy as np\n",
    "from pysrc.papers.data import AnalysisData\n",
    "from IPython.display import HTML, display\n",
    "\n",
    "def filter_by_connectivity(df, graph, percentile=75, max_count=None):\n",
    "    # Step 1: Compute connectivity (without modifying df)\n",
    "    connectivity = df['id'].apply(lambda pid: len(list(graph.neighbors(pid))))\n",
    "\n",
    "    # Step 2: Compute the percentile threshold\n",
    "    threshold = np.percentile(connectivity, percentile)\n",
    "\n",
    "    # Step 3: Get mask for nodes above threshold\n",
    "    above_threshold_mask = connectivity >= threshold\n",
    "\n",
    "    # Step 4: Apply the mask\n",
    "    filtered_df = df[above_threshold_mask].copy()\n",
    "    filtered_df['connections'] = connectivity[above_threshold_mask].values\n",
    "\n",
    "    # Step 5: If max_count is specified, take top N by connections\n",
    "    if max_count is not None and len(filtered_df) > max_count:\n",
    "        filtered_df = filtered_df.sort_values('connections', ascending=False).head(max_count)\n",
    "\n",
    "    return filtered_df\n",
    "\n",
    "def render_table(entities):\n",
    "    html = \"\"\"\n",
    "    <style>\n",
    "        .collapse-content { display: none; margin-top: 5px; }\n",
    "        .toggle-button { cursor: pointer; color: blue; text-decoration: underline; }\n",
    "        th { text-align: left; }\n",
    "    </style>\n",
    "    <script>\n",
    "        function toggleCollapse(id) {\n",
    "            var x = document.getElementById(id);\n",
    "            x.style.display = (x.style.display === \"none\") ? \"block\" : \"none\";\n",
    "        }\n",
    "    </script>\n",
    "    <table border=\"1\" style=\"border-collapse: collapse; width: 100%;\">\n",
    "        <thead>\n",
    "            <tr>\n",
    "                <th>#</th>\n",
    "                <th>Name</th>\n",
    "                <th>Context</th>\n",
    "                <th>Total Connections</th>\n",
    "                <th>Papers</th>\n",
    "            </tr>\n",
    "        </thead>\n",
    "        <tbody>\n",
    "    \"\"\"\n",
    "    for idx, entity in enumerate(sorted(entities, key=lambda g: g['total_connections'], reverse=True), start=1):\n",
    "        collapse_id = f\"collapse-{idx}\"\n",
    "        paper_links = \"<br>\".join(\n",
    "            f'<a href=\"/paper/{pid}\" target=\"_blank\">{pid}</a>' for pid in entity[\"cited_in\"]\n",
    "        )\n",
    "        html += f\"\"\"\n",
    "        <tr>\n",
    "            <td>{idx}</td>\n",
    "            <td>{entity['name']}</td>\n",
    "            <td>{entity['context']}</td>\n",
    "            <td>{entity['total_connections']}</td>\n",
    "            <td>\n",
    "                <span class=\"toggle-button\" onclick=\"toggleCollapse('{collapse_id}')\">\n",
    "                    Show Papers ({len(entity['cited_in'])})\n",
    "                </span>\n",
    "                <div id=\"{collapse_id}\" class=\"collapse-content\">{paper_links}</div>\n",
    "            </td>\n",
    "        </tr>\n",
    "        \"\"\"\n",
    "    html += \"</tbody></table>\"\n",
    "    display(HTML(html))\n",
    "\n",
    "###### Remove this part if you're getting json from pubtrends API\n",
    "\n",
    "# Replace 'your_file.json' with the actual path to your JSON file\n",
    "file_path = 'pubmed-drug-resistance-in-cancer.json'\n",
    "\n",
    "# Open and load the JSON file\n",
    "with open(file_path, 'r', encoding='utf-8') as file:\n",
    "    data = json.load(file)\n",
    "\n",
    "ex = AnalysisData.from_json(data)\n",
    "\n",
    "######\n",
    "\n",
    "highly_connected_df = filter_by_connectivity(\n",
    "    ex.df,\n",
    "    ex.papers_graph,\n",
    "    percentile=90,\n",
    "    max_count=50  # cap the result if it's too large\n",
    ")\n",
    "\n",
    "abstract_entries = highly_connected_df[['id', 'abstract']].to_dict(orient='records')\n",
    "\n",
    "# Convert to formatted string for LLM\n",
    "abstracts_json = json.dumps(abstract_entries, ensure_ascii=False, indent=2)\n",
    "\n",
    "# 1. Set your function URL\n",
    "FUNCTION_URL = \"URL_HERE\"\n",
    "\n",
    "# 2. System prompt enum (must match server-side allowed value), here are represented all types\n",
    "si_mode = \"GENES_EXTRACTION\"\n",
    "# si_mode = \"SUBSTANCES_EXTRACTION\"\n",
    "# si_mode = \"CONDITIONS_EXTRACTION\"\n",
    "# si_mode = \"PROTEINS_EXTRACTION\"\n",
    "\n",
    "# 4. Make the POST request with abstracts and si_mode\n",
    "response = requests.post(\n",
    "    f\"{FUNCTION_URL}?si_mode={si_mode}\",\n",
    "    json=abstracts_json,\n",
    "    headers={\"Content-Type\": \"application/json\"}\n",
    ")\n",
    "\n",
    "# 5. Handle response\n",
    "if response.status_code == 200:\n",
    "    data = response.json()\n",
    "    connections_by_pid = dict(zip(highly_connected_df['id'], highly_connected_df['connections']))\n",
    "    for entity in data:\n",
    "        entity[\"total_connections\"] = sum(\n",
    "            connections_by_pid.get(pid, 0) for pid in entity.get(\"cited_in\", [])\n",
    "        )\n",
    "\n",
    "    print(\"✅ Entities Extracted:\\n\")\n",
    "    render_table(data)\n",
    "else:\n",
    "    print(f\"❌ Error: {response.status_code}\")\n",
    "    print(response.json())"
   ],
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/Dmitry.Bozhko/work/miniconda3/envs/pubtrends/lib/python3.10/site-packages/networkx/readwrite/json_graph/node_link.py:287: FutureWarning: \n",
      "The default value will be changed to `edges=\"edges\" in NetworkX 3.6.\n",
      "\n",
      "To make this warning go away, explicitly set the edges kwarg, e.g.:\n",
      "\n",
      "  nx.node_link_graph(data, edges=\"links\") to preserve current behavior, or\n",
      "  nx.node_link_graph(data, edges=\"edges\") for forward compatibility.\n",
      "  warnings.warn(\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "✅ Entities Extracted:\n",
      "\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ],
      "text/html": [
       "\n",
       "    <style>\n",
       "        .collapse-content { display: none; margin-top: 5px; }\n",
       "        .toggle-button { cursor: pointer; color: blue; text-decoration: underline; }\n",
       "        th { text-align: left; }\n",
       "    </style>\n",
       "    <script>\n",
       "        function toggleCollapse(id) {\n",
       "            var x = document.getElementById(id);\n",
       "            x.style.display = (x.style.display === \"none\") ? \"block\" : \"none\";\n",
       "        }\n",
       "    </script>\n",
       "    <table border=\"1\" style=\"border-collapse: collapse; width: 100%;\">\n",
       "        <thead>\n",
       "            <tr>\n",
       "                <th>#</th>\n",
       "                <th>Name</th>\n",
       "                <th>Context</th>\n",
       "                <th>Total Connections</th>\n",
       "                <th>Papers</th>\n",
       "            </tr>\n",
       "        </thead>\n",
       "        <tbody>\n",
       "    \n",
       "        <tr>\n",
       "            <td>1</td>\n",
       "            <td>miR-137</td>\n",
       "            <td>miR-137 level is extremely low in cisplatin resistant ovarian cancer cells, correlating with higher levels of c-Myc and EZH2 expression. In resistant cells c-Myc enhances the expression of EZH2 by directly suppressing miR-137 that targets EZH2 mRNA. Cisplatin treatment activates c-Myc-miR-137-EZH2 pathway.</td>\n",
       "            <td>177</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-1')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-1\" class=\"collapse-content\"><a href=\"/paper/30166592\" target=\"_blank\">30166592</a><br><a href=\"/paper/30166592\" target=\"_blank\">30166592</a><br><a href=\"/paper/30166592\" target=\"_blank\">30166592</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>2</td>\n",
       "            <td>ATM</td>\n",
       "            <td>ATM, a primary mediator of the DNA damage response, as a potential target of miR-203. ATM mRNA and protein levels were significantly down-regulated in CRC cells with acquired resistance to oxaliplatin. ATM is a bona fide target of miR-203 in CRC cells.</td>\n",
       "            <td>138</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-2')\">\n",
       "                    Show Papers (4)\n",
       "                </span>\n",
       "                <div id=\"collapse-2\" class=\"collapse-content\"><a href=\"/paper/24145123\" target=\"_blank\">24145123</a><br><a href=\"/paper/24145123\" target=\"_blank\">24145123</a><br><a href=\"/paper/24145123\" target=\"_blank\">24145123</a><br><a href=\"/paper/28212573\" target=\"_blank\">28212573</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>3</td>\n",
       "            <td>miR-186</td>\n",
       "            <td>miR-186 expression correlated with decreased Twist1 expression, chemoresistance and poor prognosis in epithelial ovarian cancer (EOC) patients. Introducing miR-186 into EOC cells led to a reduction in twist family bHLH transcription factor 1 (Twist1) expression along with morphological, functional and molecular changes consistent with mesenchymal-to-epithelial transition, G1 cell-cycle arrest and enhanced cell apoptosis, which consequently rendered the cells more sensitive to cisplatin in vitro and in vivo. The EMT and drug resistance reversal in response to miR-186 was mediated by Twist1.</td>\n",
       "            <td>135</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-3')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-3\" class=\"collapse-content\"><a href=\"/paper/25867064\" target=\"_blank\">25867064</a><br><a href=\"/paper/25867064\" target=\"_blank\">25867064</a><br><a href=\"/paper/25867064\" target=\"_blank\">25867064</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>4</td>\n",
       "            <td>Twist1</td>\n",
       "            <td>Twist1 expression correlated with decreased miR-186 expression, chemoresistance and poor prognosis in epithelial ovarian cancer (EOC) patients. Introducing miR-186 into EOC cells led to a reduction in twist family bHLH transcription factor 1 (Twist1) expression along with morphological, functional and molecular changes consistent with mesenchymal-to-epithelial transition, G1 cell-cycle arrest and enhanced cell apoptosis, which consequently rendered the cells more sensitive to cisplatin in vitro and in vivo. The EMT and drug resistance reversal in response to miR-186 was mediated by Twist1.</td>\n",
       "            <td>135</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-4')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-4\" class=\"collapse-content\"><a href=\"/paper/25867064\" target=\"_blank\">25867064</a><br><a href=\"/paper/25867064\" target=\"_blank\">25867064</a><br><a href=\"/paper/25867064\" target=\"_blank\">25867064</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>5</td>\n",
       "            <td>EZH2</td>\n",
       "            <td>EZH2 has been implicated in regulating cisplatin resistance in ovarian cancer. In resistant cells c-Myc enhances the expression of EZH2 by directly suppressing miR-137 that targets EZH2 mRNA, and increased expression of EZH2 activates cellular survival pathways, resulting in the resistance to cisplatin. Cisplatin treatment activates c-Myc-miR-137-EZH2 pathway.</td>\n",
       "            <td>118</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-5')\">\n",
       "                    Show Papers (2)\n",
       "                </span>\n",
       "                <div id=\"collapse-5\" class=\"collapse-content\"><a href=\"/paper/30166592\" target=\"_blank\">30166592</a><br><a href=\"/paper/30166592\" target=\"_blank\">30166592</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>6</td>\n",
       "            <td>AR</td>\n",
       "            <td>The effectiveness of androgen receptor (AR) inhibitors in recurrent disease is variable. Single CTCs from each individual display considerable heterogeneity, including expression of AR gene mutations and splicing variants. Ectopic expression of Wnt5a in prostate cancer cells attenuates the antiproliferative effect of AR inhibition, whereas its suppression in drug-resistant cells restores partial sensitivity, a correlation also evident in an established mouse model.</td>\n",
       "            <td>117</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-6')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-6\" class=\"collapse-content\"><a href=\"/paper/26383955\" target=\"_blank\">26383955</a><br><a href=\"/paper/26383955\" target=\"_blank\">26383955</a><br><a href=\"/paper/26383955\" target=\"_blank\">26383955</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>7</td>\n",
       "            <td>Wnts</td>\n",
       "            <td>The major reprogramming regulators in fibroblast-exosomes are Wnts. Exosomal Wnts were found to increase Wnt activity and drug resistance in differentiated CRC cells, and inhibiting Wnt release diminished this effect in vitro and in vivo. Exosomal Wnts derived from fibroblasts could induce the dedifferentiation of cancer cells to promote chemoresistance in CRC.</td>\n",
       "            <td>111</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-7')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-7\" class=\"collapse-content\"><a href=\"/paper/30390075\" target=\"_blank\">30390075</a><br><a href=\"/paper/30390075\" target=\"_blank\">30390075</a><br><a href=\"/paper/30390075\" target=\"_blank\">30390075</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>8</td>\n",
       "            <td>KRAS</td>\n",
       "            <td>Therapeutic targeting of KRAS-mutant lung adenocarcinoma represents a major goal of clinical oncology. KRAS itself has proved difficult to inhibit, and the effectiveness of agents that target key KRAS effectors has been thwarted by activation of compensatory or parallel pathways that limit their efficacy as single agents. FGFR1 mediates adaptive resistance to trametinib and validate a combinatorial approach for treating KRAS-mutant lung cancer.</td>\n",
       "            <td>111</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-8')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-8\" class=\"collapse-content\"><a href=\"/paper/27338794\" target=\"_blank\">27338794</a><br><a href=\"/paper/27338794\" target=\"_blank\">27338794</a><br><a href=\"/paper/27338794\" target=\"_blank\">27338794</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>9</td>\n",
       "            <td>FGFR1</td>\n",
       "            <td>Trametinib provokes a compensatory response involving the fibroblast growth factor receptor 1 (FGFR1) that leads to signalling rebound and adaptive drug resistance. Genetic or pharmacological inhibition of FGFR1 in combination with trametinib enhances tumour cell death in vitro and in vivo. FGFR1 can mediate adaptive resistance to trametinib and validate a combinatorial approach for treating KRAS-mutant lung cancer.</td>\n",
       "            <td>111</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-9')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-9\" class=\"collapse-content\"><a href=\"/paper/27338794\" target=\"_blank\">27338794</a><br><a href=\"/paper/27338794\" target=\"_blank\">27338794</a><br><a href=\"/paper/27338794\" target=\"_blank\">27338794</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>10</td>\n",
       "            <td>Nrf2</td>\n",
       "            <td>The Nrf2 transcription factor, which is the master regulator of cellular responses to oxidative stress, is preactivated in de-differentiated cells. In de-differentiated cells, Nrf2 is not activated by oxidation but rather through a noncanonical mechanism involving its phosphorylation by the ER membrane kinase PERK. Constitutive PERK-Nrf2 signaling protects de-differentiated cells from chemotherapy by reducing ROS levels and increasing drug efflux.</td>\n",
       "            <td>111</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-10')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-10\" class=\"collapse-content\"><a href=\"/paper/25203443\" target=\"_blank\">25203443</a><br><a href=\"/paper/25203443\" target=\"_blank\">25203443</a><br><a href=\"/paper/25203443\" target=\"_blank\">25203443</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>11</td>\n",
       "            <td>miR-155</td>\n",
       "            <td>The long-term exposure of GEM increased miR-155 expression in PDAC cells. The increase of miR-155 induced two different functions; exosome secretion and chemoresistance ability via facilitating the anti-apoptotic activity. Exosome deliver the miR-155 into the other PDAC cells and induce the following function.</td>\n",
       "            <td>108</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-11')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-11\" class=\"collapse-content\"><a href=\"/paper/28198398\" target=\"_blank\">28198398</a><br><a href=\"/paper/28198398\" target=\"_blank\">28198398</a><br><a href=\"/paper/28198398\" target=\"_blank\">28198398</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>12</td>\n",
       "            <td>miR-203</td>\n",
       "            <td>The miR-203 microRNA is up-regulated in three of three oxaliplatin-resistant CRC cell lines. Exogenous expression of miR-203 in chemo-nave CRC cells induced oxaliplatin resistance. ATM is a bona fide target of miR-203 in CRC cells.</td>\n",
       "            <td>108</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-12')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-12\" class=\"collapse-content\"><a href=\"/paper/24145123\" target=\"_blank\">24145123</a><br><a href=\"/paper/24145123\" target=\"_blank\">24145123</a><br><a href=\"/paper/24145123\" target=\"_blank\">24145123</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>13</td>\n",
       "            <td>miR-130b</td>\n",
       "            <td>MicroRNA-130b-3p (miR-130b) mediates the chemoresistance and proliferation of breast cancer. MiR-130b was found to be up-regulated in tumor tissues versus adjacent tissues of breast cancer, as well as in adriamycin (ADR) resistant breast cancer cell line (MCF-7/ADR) versus its parental line (MCF-7) and the non-malignant breast epithelial cell line (MCF-10A), demonstrating its crucial relevance for breast cancer biology. MiR-130b targets PTEN to induce MDR, proliferation, and apoptosis via PI3K/Akt signaling pathway.</td>\n",
       "            <td>108</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-13')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-13\" class=\"collapse-content\"><a href=\"/paper/28165066\" target=\"_blank\">28165066</a><br><a href=\"/paper/28165066\" target=\"_blank\">28165066</a><br><a href=\"/paper/28165066\" target=\"_blank\">28165066</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>14</td>\n",
       "            <td>PTEN</td>\n",
       "            <td>PTEN was a direct target of miR-130b and inversely correlated with miR-130b expression in breast cancer. MiR-130b targets PTEN to induce MDR, proliferation, and apoptosis via PI3K/Akt signaling pathway. MiR-130b mediated the activity of phosphoinositide-3 kinase (PI3K)/Akt signaling pathway as well as the chemoresistance and proliferation of breast cancer cell lines, which was partially blocked following knockdown of PTEN.</td>\n",
       "            <td>108</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-14')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-14\" class=\"collapse-content\"><a href=\"/paper/28165066\" target=\"_blank\">28165066</a><br><a href=\"/paper/28165066\" target=\"_blank\">28165066</a><br><a href=\"/paper/28165066\" target=\"_blank\">28165066</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>15</td>\n",
       "            <td>HK2</td>\n",
       "            <td>Hexokinase 2 (HK2) phosphorylates glucose to generate glucose-6-phosphate, the rate-limiting step in glycolysis. Increased HK2 levels were detected in drug-resistant human ovarian cancer cells and tissues. HK2 promotes cisplatin resistance in ovarian cancer by enhancing drug-induced, ERK-mediated autophagy.</td>\n",
       "            <td>105</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-15')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-15\" class=\"collapse-content\"><a href=\"/paper/29247711\" target=\"_blank\">29247711</a><br><a href=\"/paper/29247711\" target=\"_blank\">29247711</a><br><a href=\"/paper/29247711\" target=\"_blank\">29247711</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>16</td>\n",
       "            <td>CD24</td>\n",
       "            <td>CD24, is overexpressed in tumor tissues and sorafenib-resistant hepatocellular carcinoma cell lines. There is a positive correlation between CD24 expression levels and sorafenib resistance. CD24 regulates sorafenib resistance via activating autophagy in HCC.</td>\n",
       "            <td>102</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-16')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-16\" class=\"collapse-content\"><a href=\"/paper/29844385\" target=\"_blank\">29844385</a><br><a href=\"/paper/29844385\" target=\"_blank\">29844385</a><br><a href=\"/paper/29844385\" target=\"_blank\">29844385</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>17</td>\n",
       "            <td>Pygo2</td>\n",
       "            <td>Pygo2, a newly identified Wnt/-catenin pathway component, was the most upregulated gene in the resistant cells. Pygo2 activated MDR1 expression in the resistant cells via the Wnt/-catenin pathway. The inhibition of Pygo2 expression restored the chemotherapeutic drug sensitivity of the resistant cells and reduced the breast cancer stem cell population in these cells in response to chemotherapy.</td>\n",
       "            <td>96</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-17')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-17\" class=\"collapse-content\"><a href=\"/paper/26876203\" target=\"_blank\">26876203</a><br><a href=\"/paper/26876203\" target=\"_blank\">26876203</a><br><a href=\"/paper/26876203\" target=\"_blank\">26876203</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>18</td>\n",
       "            <td>AURKA</td>\n",
       "            <td>Residual disease and acquired resistance in response to EGFR inhibitors requires Aurora kinase A (AURKA) activity. Nongenetic resistance through the activation of AURKA by its coactivator TPX2 emerges in response to chronic EGFR inhibition where it mitigates drug-induced apoptosis. Treatment-induced activation of AURKA is associated with resistance to EGFR inhibitors in vitro, in vivo and in most individuals with EGFR-mutant lung adenocarcinoma.</td>\n",
       "            <td>93</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-18')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-18\" class=\"collapse-content\"><a href=\"/paper/30478424\" target=\"_blank\">30478424</a><br><a href=\"/paper/30478424\" target=\"_blank\">30478424</a><br><a href=\"/paper/30478424\" target=\"_blank\">30478424</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>19</td>\n",
       "            <td>AXL</td>\n",
       "            <td>SCLC models with primary resistance to AZD1775 express high levels of AXL and phosphorylated S6 and that WEE1/AXL or WEE1/mTOR inhibitor combinations overcome resistance in vitro and in vivo. AXL, independently and via mTOR, activates the ERK pathway, leading to recruitment and activation of another G2-checkpoint protein, CHK1. AZD1775 acquired resistance models demonstrated upregulation of AXL, pS6, and MET, and resistance was overcome with the addition of AXL (TP0903), dual-AXL/MET (cabozantinib), or mTOR (RAD001) inhibitors.</td>\n",
       "            <td>93</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-19')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-19\" class=\"collapse-content\"><a href=\"/paper/28698200\" target=\"_blank\">28698200</a><br><a href=\"/paper/28698200\" target=\"_blank\">28698200</a><br><a href=\"/paper/28698200\" target=\"_blank\">28698200</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>20</td>\n",
       "            <td>BCL2</td>\n",
       "            <td>miR-139-5p targeted the BCL2 pathway to reduce tumour metastasis and drug sensitivity in CRC. HCC tissues with lower miR-34a expression displayed higher expression of Bcl-2 protein than those with high expression of miR-34a; therefore, an inverse correlation is evident between the miR-34a level and Bcl-2 expression. MiR-34a binds the 3'-UTR of the Bcl-2 mRNA and represses its translation.</td>\n",
       "            <td>91</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-20')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-20\" class=\"collapse-content\"><a href=\"/paper/27244080\" target=\"_blank\">27244080</a><br><a href=\"/paper/23862748\" target=\"_blank\">23862748</a><br><a href=\"/paper/23862748\" target=\"_blank\">23862748</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>21</td>\n",
       "            <td>EGFR</td>\n",
       "            <td>Epidermal growth factor receptor (EGFR)/BRAF inhibition down-regulates mismatch repair (MMR) and homologous recombination DNA-repair genes and concomitantly up-regulates error-prone polymerases in drug-tolerant (persister) cells. Single-cell analyses of patient-derived models and clinical samples from glioblastoma patients treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) demonstrate that tumor cells reversibly up-regulate or suppress mutant EGFR expression, conferring distinct cellular phenotypes to reach an optimal equilibrium for growth. Resistance to EGFR TKIs is shown to occur by elimination of mutant EGFR from extrachromosomal DNA.</td>\n",
       "            <td>90</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-21')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-21\" class=\"collapse-content\"><a href=\"/paper/31699882\" target=\"_blank\">31699882</a><br><a href=\"/paper/24310612\" target=\"_blank\">24310612</a><br><a href=\"/paper/24310612\" target=\"_blank\">24310612</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>22</td>\n",
       "            <td>miR-34a</td>\n",
       "            <td>MiR-34a, a direct target of p53, has been shown to target several molecules associated with the cell cycle and cell survival pathways, and its dysregulation is implicated in cancer drug resistance or sensitivity in several human cancers. HCC tissues with lower miR-34a expression displayed higher expression of Bcl-2 protein than those with high expression of miR-34a; therefore, an inverse correlation is evident between the miR-34a level and Bcl-2 expression. MiR-34a binds the 3'-UTR of the Bcl-2 mRNA and represses its translation.</td>\n",
       "            <td>90</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-22')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-22\" class=\"collapse-content\"><a href=\"/paper/23862748\" target=\"_blank\">23862748</a><br><a href=\"/paper/23862748\" target=\"_blank\">23862748</a><br><a href=\"/paper/23862748\" target=\"_blank\">23862748</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>23</td>\n",
       "            <td>Wnt</td>\n",
       "            <td>Secreted Wnt signals maintain stem cells in various epithelial tissues, including in lung development and regeneration. Mouse and human lung adenocarcinomas display hierarchical features with two distinct subpopulations, one with high Wnt signalling activity and another forming a niche that provides the Wnt ligand. Genetic perturbation of Wnt production or signalling suppressed tumour progression.</td>\n",
       "            <td>90</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-23')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-23\" class=\"collapse-content\"><a href=\"/paper/28489818\" target=\"_blank\">28489818</a><br><a href=\"/paper/28489818\" target=\"_blank\">28489818</a><br><a href=\"/paper/28489818\" target=\"_blank\">28489818</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>24</td>\n",
       "            <td>miR-128-3p</td>\n",
       "            <td>Aberrant expression of small noncoding RNA, miR-128-3p, has been shown to be a key regulator in tumorigenesis and cancer development. In our established stable oxaliplatin-resistant CRC cell lines, in vitro and vivo studies revealed miR-128-3p suppressed EMT and increased intracellular oxaliplatin accumulation. MiR-128-3p delivery via exosomes represents a novel strategy enhancing chemosensitivity in CRC through negative regulation of Bmi1 and MRP5.</td>\n",
       "            <td>90</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-24')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-24\" class=\"collapse-content\"><a href=\"/paper/30890168\" target=\"_blank\">30890168</a><br><a href=\"/paper/30890168\" target=\"_blank\">30890168</a><br><a href=\"/paper/30890168\" target=\"_blank\">30890168</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>25</td>\n",
       "            <td>AR</td>\n",
       "            <td>Prostate cancer has the second highest incidence among cancers in men worldwide and is the second leading cause of cancer deaths of men in the United States. Some success against CRPC has been achieved by drugs that target AR signaling, but secondary resistance invariably emerges, and new therapies are urgently needed. Unlike BET inhibitors, ARV-771 results in suppression of both AR signaling and AR levels and leads to tumor regression in a CRPC mouse xenograft model.</td>\n",
       "            <td>90</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-25')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-25\" class=\"collapse-content\"><a href=\"/paper/27274052\" target=\"_blank\">27274052</a><br><a href=\"/paper/27274052\" target=\"_blank\">27274052</a><br><a href=\"/paper/27274052\" target=\"_blank\">27274052</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>26</td>\n",
       "            <td>ALDH</td>\n",
       "            <td>We define a requirement for the previously established cancer stem cell marker ALDH (aldehyde dehydrogenase) in the maintenance of this drug-tolerant subpopulation. We find that ALDH protects the drug-tolerant subpopulation from the potentially toxic effects of elevated levels of reactive oxygen species (ROS) in these cells, and pharmacologic disruption of ALDH activity leads to accumulation of ROS to toxic levels, consequent DNA damage, and apoptosis specifically within the drug-tolerant subpopulation.</td>\n",
       "            <td>87</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-26')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-26\" class=\"collapse-content\"><a href=\"/paper/24812274\" target=\"_blank\">24812274</a><br><a href=\"/paper/24812274\" target=\"_blank\">24812274</a><br><a href=\"/paper/24812274\" target=\"_blank\">24812274</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>27</td>\n",
       "            <td>ONECUT2</td>\n",
       "            <td>Here we identify the transcription factor ONECUT2 (OC2) as a master regulator of AR networks in metastatic castration-resistant prostate cancer (mCRPC). OC2 acts as a survival factor in mCRPC models, suppresses the AR transcriptional program by direct regulation of AR target genes and the AR licensing factor FOXA1, and activates genes associated with neural differentiation and progression to lethal disease. OC2 is also a potential drug target in the metastatic phase of aggressive PC.</td>\n",
       "            <td>87</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-27')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-27\" class=\"collapse-content\"><a href=\"/paper/30478421\" target=\"_blank\">30478421</a><br><a href=\"/paper/30478421\" target=\"_blank\">30478421</a><br><a href=\"/paper/30478421\" target=\"_blank\">30478421</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>28</td>\n",
       "            <td>GBCDRlnc1</td>\n",
       "            <td>We found a lncRNA ENST00000425894 termed gallbladder cancer drug resistance-associated lncRNA1 (GBCDRlnc1) that serves as a critical regulator in gallbladder cancer chemoresistance. Knockdown of GBCDRlnc1, via inhibiting autophagy at initial stage, enhanced the sensitivity of Dox-resistant gallbladder cancer cells to Dox in vitro and in vivo. GBCDRlnc1 interacts with phosphoglycerate kinase 1 and inhibits its ubiquitination in Dox-resistant gallbladder cancer cells, which leads to the down-regulation of autophagy initiator ATG5-ATG12 conjugate.</td>\n",
       "            <td>87</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-28')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-28\" class=\"collapse-content\"><a href=\"/paper/30953511\" target=\"_blank\">30953511</a><br><a href=\"/paper/30953511\" target=\"_blank\">30953511</a><br><a href=\"/paper/30953511\" target=\"_blank\">30953511</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>29</td>\n",
       "            <td>YAP</td>\n",
       "            <td>YAP is a key component of the Hippo signaling pathway and plays a critical role in the development and progression of multiple cancer types, including ovarian cancer. High YAP expression levels were positively correlated with TEAD4 gene expression, and their co-expression was a prognostic marker for poor ovarian cancer survival. YAP promotes ovarian cancer cell growth and tumorigenesis both in vitro and in vivo.</td>\n",
       "            <td>87</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-29')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-29\" class=\"collapse-content\"><a href=\"/paper/24622501\" target=\"_blank\">24622501</a><br><a href=\"/paper/24622501\" target=\"_blank\">24622501</a><br><a href=\"/paper/24622501\" target=\"_blank\">24622501</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>30</td>\n",
       "            <td>miR-1246</td>\n",
       "            <td>This study aims to validate exosomal microRNA-1246 (miR-1246) as a serum biomarker for breast cancer and understand the underlying mechanism in breast cancer progression. miR-1246 is highly expressed in metastatic breast cancer MDA-MB-231 cells compared to non-metastatic breast cancer cells or non-malignant breast cells. Treatment with exosomes derived from MDA-MB-231 cells could enhance the viability, migration and chemotherapy resistance of non-malignant HMLE cells.</td>\n",
       "            <td>87</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-30')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-30\" class=\"collapse-content\"><a href=\"/paper/29216623\" target=\"_blank\">29216623</a><br><a href=\"/paper/29216623\" target=\"_blank\">29216623</a><br><a href=\"/paper/29216623\" target=\"_blank\">29216623</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>31</td>\n",
       "            <td>NRF2</td>\n",
       "            <td>Activation of the cell protective stress response gene NRF2 by KRAS is responsible for its ability to promote drug resistance. RNAi-mediated silencing of NRF2 was sufficient to reverse resistance to cisplatin elicited by ectopic expression of oncogenic KRAS in NSCLC cells. Suppressing the NRF2 pathway with the chemical inhibitor brusatol enhanced the antitumor efficacy of cisplatin.</td>\n",
       "            <td>87</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-31')\">\n",
       "                    Show Papers (3)\n",
       "                </span>\n",
       "                <div id=\"collapse-31\" class=\"collapse-content\"><a href=\"/paper/25339352\" target=\"_blank\">25339352</a><br><a href=\"/paper/25339352\" target=\"_blank\">25339352</a><br><a href=\"/paper/25339352\" target=\"_blank\">25339352</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>32</td>\n",
       "            <td>ATG5</td>\n",
       "            <td>Inhibition of autophagy, by in vitro chloroquine treatment or CRISPR/Cas9 ATG5 knockout, impaired canonical CSC properties, such as viability, the ability to form spheroidal structures in vitro, and in vivo tumorigenic potential. GBCDRlnc1 interacts with phosphoglycerate kinase 1 and inhibits its ubiquitination in Dox-resistant gallbladder cancer cells, which leads to the down-regulation of autophagy initiator ATG5-ATG12 conjugate.</td>\n",
       "            <td>64</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-32')\">\n",
       "                    Show Papers (2)\n",
       "                </span>\n",
       "                <div id=\"collapse-32\" class=\"collapse-content\"><a href=\"/paper/28726781\" target=\"_blank\">28726781</a><br><a href=\"/paper/30953511\" target=\"_blank\">30953511</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>33</td>\n",
       "            <td>KRAS</td>\n",
       "            <td>Integrin (v), in the unliganded state, recruits KRAS and RalB to the tumour cell plasma membrane, leading to the activation of TBK1 and NF-B. (v) expression and the resulting KRAS-RalB-NF-B pathway were both necessary and sufficient for tumour initiation, anchorage independence, self-renewal and erlotinib resistance.</td>\n",
       "            <td>64</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-33')\">\n",
       "                    Show Papers (2)\n",
       "                </span>\n",
       "                <div id=\"collapse-33\" class=\"collapse-content\"><a href=\"/paper/24747441\" target=\"_blank\">24747441</a><br><a href=\"/paper/24747441\" target=\"_blank\">24747441</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>34</td>\n",
       "            <td>BMI1</td>\n",
       "            <td>Curcumin suppressed EMT in 5FUR cells by downregulating BMI1, SUZ12 and EZH2 transcripts, key mediators of cancer stemness-related polycomb repressive complex subunits. MiR-128-3p overexpression up-regulated E-cadherin levels and inhibited oxaliplatin-induced EMT by suppressing Bmi1 expression in resistant cells.</td>\n",
       "            <td>63</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-34')\">\n",
       "                    Show Papers (2)\n",
       "                </span>\n",
       "                <div id=\"collapse-34\" class=\"collapse-content\"><a href=\"/paper/25653233\" target=\"_blank\">25653233</a><br><a href=\"/paper/30890168\" target=\"_blank\">30890168</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>35</td>\n",
       "            <td>Stat3</td>\n",
       "            <td>Attenuating the autophagy regulator FIP200 diminished the tumor-initiating properties of both ALDH(+) and CD29(hi)CD61(+) BCSC, as achieved by impairing either the Stat3 or TGF/Smad pathways, respectively. BBI608, a small molecule identified by its ability to inhibit gene transcription driven by Stat3 and cancer stemness properties, can inhibit stemness gene expression and block spherogenesis of or kill stemness-high cancer cells isolated from a variety of cancer types.</td>\n",
       "            <td>60</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-35')\">\n",
       "                    Show Papers (2)\n",
       "                </span>\n",
       "                <div id=\"collapse-35\" class=\"collapse-content\"><a href=\"/paper/27197172\" target=\"_blank\">27197172</a><br><a href=\"/paper/25605917\" target=\"_blank\">25605917</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>36</td>\n",
       "            <td>SLFN11</td>\n",
       "            <td>PARP inhibitor response was not associated with mutations in homologous recombination (HR) genes (e.g., BRCA1/2) or HRD scores. Instead, we found several proteomic markers that predicted PDX response, including high levels of SLFN11 and E-cadherin and low ATM. Silencing SLFN11 reduced in vitro sensitivity and drug-induced DNA damage.</td>\n",
       "            <td>60</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-36')\">\n",
       "                    Show Papers (2)\n",
       "                </span>\n",
       "                <div id=\"collapse-36\" class=\"collapse-content\"><a href=\"/paper/28212573\" target=\"_blank\">28212573</a><br><a href=\"/paper/28212573\" target=\"_blank\">28212573</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>37</td>\n",
       "            <td>c-Myc</td>\n",
       "            <td>c-Myc has been implicated in regulating cisplatin resistance in ovarian cancer. In resistant cells c-Myc enhances the expression of EZH2 by directly suppressing miR-137 that targets EZH2 mRNA, and increased expression of EZH2 activates cellular survival pathways, resulting in the resistance to cisplatin. Cisplatin treatment activates c-Myc-miR-137-EZH2 pathway.</td>\n",
       "            <td>59</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-37')\">\n",
       "                    Show Papers (1)\n",
       "                </span>\n",
       "                <div id=\"collapse-37\" class=\"collapse-content\"><a href=\"/paper/30166592\" target=\"_blank\">30166592</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>38</td>\n",
       "            <td>MYC</td>\n",
       "            <td>Suppression of MYC and subsequent increase of PGC-1 were identified as key determinants for the OXPHOS dependency of CSCs, which was abolished in resistant CSC clones. Resistance could also be prevented/reversed for metformin by genetic/pharmacological inhibition of MYC.</td>\n",
       "            <td>58</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-38')\">\n",
       "                    Show Papers (2)\n",
       "                </span>\n",
       "                <div id=\"collapse-38\" class=\"collapse-content\"><a href=\"/paper/26365176\" target=\"_blank\">26365176</a><br><a href=\"/paper/26365176\" target=\"_blank\">26365176</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>39</td>\n",
       "            <td>TEAD4</td>\n",
       "            <td>High YAP expression levels were positively correlated with TEAD4 gene expression, and their co-expression was a prognostic marker for poor ovarian cancer survival. High YAP and TEAD4 expression is a prognostic marker for ovarian cancer progression and a potential target for ovarian cancer treatment.</td>\n",
       "            <td>58</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-39')\">\n",
       "                    Show Papers (2)\n",
       "                </span>\n",
       "                <div id=\"collapse-39\" class=\"collapse-content\"><a href=\"/paper/24622501\" target=\"_blank\">24622501</a><br><a href=\"/paper/24622501\" target=\"_blank\">24622501</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>40</td>\n",
       "            <td>Wnt5a</td>\n",
       "            <td>Ectopic expression of Wnt5a in prostate cancer cells attenuates the antiproliferative effect of AR inhibition, whereas its suppression in drug-resistant cells restores partial sensitivity, a correlation also evident in an established mouse model.</td>\n",
       "            <td>39</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-40')\">\n",
       "                    Show Papers (1)\n",
       "                </span>\n",
       "                <div id=\"collapse-40\" class=\"collapse-content\"><a href=\"/paper/26383955\" target=\"_blank\">26383955</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>41</td>\n",
       "            <td>Hck</td>\n",
       "            <td>Exposure to a taxane induces phenotypic cell state transition towards a favoured transient CD44(Hi)CD24(Hi) chemotherapy-tolerant state, leading to the activation of Src Family Kinase (SFK)/hemopoietic cell kinase (Hck) and suppression of apoptosis.</td>\n",
       "            <td>35</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-41')\">\n",
       "                    Show Papers (1)\n",
       "                </span>\n",
       "                <div id=\"collapse-41\" class=\"collapse-content\"><a href=\"/paper/25669750\" target=\"_blank\">25669750</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>42</td>\n",
       "            <td>SUZ12</td>\n",
       "            <td>Curcumin suppressed EMT in 5FUR cells by downregulating BMI1, SUZ12 and EZH2 transcripts, key mediators of cancer stemness-related polycomb repressive complex subunits.</td>\n",
       "            <td>33</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-42')\">\n",
       "                    Show Papers (1)\n",
       "                </span>\n",
       "                <div id=\"collapse-42\" class=\"collapse-content\"><a href=\"/paper/25653233\" target=\"_blank\">25653233</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>43</td>\n",
       "            <td>Pu.1</td>\n",
       "            <td>Inhibition of Lsd1 (Kdm1a) is able to overcome stable epigenetic resistance by facilitating the binding of the pioneer factor, Pu.1 and cofactor, Irf8, to nucleate new enhancers that regulate the expression of key survival genes.</td>\n",
       "            <td>33</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-43')\">\n",
       "                    Show Papers (1)\n",
       "                </span>\n",
       "                <div id=\"collapse-43\" class=\"collapse-content\"><a href=\"/paper/31222014\" target=\"_blank\">31222014</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>44</td>\n",
       "            <td>Irf8</td>\n",
       "            <td>Inhibition of Lsd1 (Kdm1a) is able to overcome stable epigenetic resistance by facilitating the binding of the pioneer factor, Pu.1 and cofactor, Irf8, to nucleate new enhancers that regulate the expression of key survival genes.</td>\n",
       "            <td>33</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-44')\">\n",
       "                    Show Papers (1)\n",
       "                </span>\n",
       "                <div id=\"collapse-44\" class=\"collapse-content\"><a href=\"/paper/31222014\" target=\"_blank\">31222014</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>45</td>\n",
       "            <td>FOXM1</td>\n",
       "            <td>Mitotic genes were repressed and FOXM1 was uniformly attenuated; however, genes involved in DNA replication were uniquely suppressed in sensitive models.</td>\n",
       "            <td>31</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-45')\">\n",
       "                    Show Papers (1)\n",
       "                </span>\n",
       "                <div id=\"collapse-45\" class=\"collapse-content\"><a href=\"/paper/25156567\" target=\"_blank\">25156567</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>46</td>\n",
       "            <td>YES1</td>\n",
       "            <td>SFK family member YES1 was amplified in osimertinib-resistant EGFR-mutant tumor cells, the effects of which were overcome by combined treatment with osimertinib and SFK inhibitors.</td>\n",
       "            <td>30</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-46')\">\n",
       "                    Show Papers (1)\n",
       "                </span>\n",
       "                <div id=\"collapse-46\" class=\"collapse-content\"><a href=\"/paper/28416483\" target=\"_blank\">28416483</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>47</td>\n",
       "            <td>NEUROD1</td>\n",
       "            <td>SCLC with mesenchymal phenotypes (i.e., loss of E-cadherin and high epithelial-to-mesenchymal transition (EMT) signature scores) displayed striking alterations in expression of miR200 family and key SCLC genes (e.g., NEUROD1, ASCL1, ALDH1A1, MYCL1).</td>\n",
       "            <td>30</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-47')\">\n",
       "                    Show Papers (1)\n",
       "                </span>\n",
       "                <div id=\"collapse-47\" class=\"collapse-content\"><a href=\"/paper/28212573\" target=\"_blank\">28212573</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>48</td>\n",
       "            <td>ASCL1</td>\n",
       "            <td>SCLC with mesenchymal phenotypes (i.e., loss of E-cadherin and high epithelial-to-mesenchymal transition (EMT) signature scores) displayed striking alterations in expression of miR200 family and key SCLC genes (e.g., NEUROD1, ASCL1, ALDH1A1, MYCL1).</td>\n",
       "            <td>30</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-48')\">\n",
       "                    Show Papers (1)\n",
       "                </span>\n",
       "                <div id=\"collapse-48\" class=\"collapse-content\"><a href=\"/paper/28212573\" target=\"_blank\">28212573</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>49</td>\n",
       "            <td>ALDH1A1</td>\n",
       "            <td>SCLC with mesenchymal phenotypes (i.e., loss of E-cadherin and high epithelial-to-mesenchymal transition (EMT) signature scores) displayed striking alterations in expression of miR200 family and key SCLC genes (e.g., NEUROD1, ASCL1, ALDH1A1, MYCL1).</td>\n",
       "            <td>30</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-49')\">\n",
       "                    Show Papers (1)\n",
       "                </span>\n",
       "                <div id=\"collapse-49\" class=\"collapse-content\"><a href=\"/paper/28212573\" target=\"_blank\">28212573</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>50</td>\n",
       "            <td>MYCL1</td>\n",
       "            <td>SCLC with mesenchymal phenotypes (i.e., loss of E-cadherin and high epithelial-to-mesenchymal transition (EMT) signature scores) displayed striking alterations in expression of miR200 family and key SCLC genes (e.g., NEUROD1, ASCL1, ALDH1A1, MYCL1).</td>\n",
       "            <td>30</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-50')\">\n",
       "                    Show Papers (1)\n",
       "                </span>\n",
       "                <div id=\"collapse-50\" class=\"collapse-content\"><a href=\"/paper/28212573\" target=\"_blank\">28212573</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>51</td>\n",
       "            <td>CD9</td>\n",
       "            <td>Exosomes derived from HCC cells were of the expected size and expressed the exosomal markers CD9 and CD63.</td>\n",
       "            <td>30</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-51')\">\n",
       "                    Show Papers (1)\n",
       "                </span>\n",
       "                <div id=\"collapse-51\" class=\"collapse-content\"><a href=\"/paper/27716356\" target=\"_blank\">27716356</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>52</td>\n",
       "            <td>CD63</td>\n",
       "            <td>Exosomes derived from HCC cells were of the expected size and expressed the exosomal markers CD9 and CD63.</td>\n",
       "            <td>30</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-52')\">\n",
       "                    Show Papers (1)\n",
       "                </span>\n",
       "                <div id=\"collapse-52\" class=\"collapse-content\"><a href=\"/paper/27716356\" target=\"_blank\">27716356</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>53</td>\n",
       "            <td>RB</td>\n",
       "            <td>Sensitive cancers suppress RB phosphorylation upon treatment with single-agent PI3K inhibitors but cancers with reduced sensitivity fail to do so. Patients' tumors that responded to the PI3K inhibitor BYL719 demonstrated suppression of pRB, while nonresponding tumors showed sustained or increased levels of pRB.</td>\n",
       "            <td>30</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-53')\">\n",
       "                    Show Papers (1)\n",
       "                </span>\n",
       "                <div id=\"collapse-53\" class=\"collapse-content\"><a href=\"/paper/25002028\" target=\"_blank\">25002028</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>54</td>\n",
       "            <td>CCNG2</td>\n",
       "            <td>miR-1246 can suppress the expression level of its target gene, Cyclin-G2 (CCNG2), indicating its functional significance.</td>\n",
       "            <td>29</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-54')\">\n",
       "                    Show Papers (1)\n",
       "                </span>\n",
       "                <div id=\"collapse-54\" class=\"collapse-content\"><a href=\"/paper/29216623\" target=\"_blank\">29216623</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>55</td>\n",
       "            <td>EZH2</td>\n",
       "            <td>We utilize these organoids to understand the biologic role of the epigenetic modifier EZH2 in driving molecular programs associated with neuroendocrine prostate cancer progression.</td>\n",
       "            <td>29</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-55')\">\n",
       "                    Show Papers (1)\n",
       "                </span>\n",
       "                <div id=\"collapse-55\" class=\"collapse-content\"><a href=\"/paper/29921838\" target=\"_blank\">29921838</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        \n",
       "        <tr>\n",
       "            <td>56</td>\n",
       "            <td>BRD4</td>\n",
       "            <td>We demonstrate the utility of this large dataset by identifying BRD4 as a potential target in luminal breast cancer and PIK3CA mutations as a resistance determinant for BET-inhibitors.</td>\n",
       "            <td>29</td>\n",
       "            <td>\n",
       "                <span class=\"toggle-button\" onclick=\"toggleCollapse('collapse-56')\">\n",
       "                    Show Papers (1)\n",
       "                </span>\n",
       "                <div id=\"collapse-56\" class=\"collapse-content\"><a href=\"/paper/26771497\" target=\"_blank\">26771497</a></div>\n",
       "            </td>\n",
       "        </tr>\n",
       "        </tbody></table>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "execution_count": 3
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 2
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython2",
   "version": "2.7.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
